Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials

By  

CANCER, Vol. 121, Iss. 11, 2015-06 ,pp. : 1737-1746

John Wiley & Sons Inc

Access to resources Recommend Favorite

MGMT promoter methylation is associated with temozolomide response and prolonged progression‐free survival in disseminated cutaneous melanoma

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 136, Iss. 12, 2015-06 ,pp. : 2844-2853

John Wiley & Sons Inc

Access to resources Recommend Favorite

Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study

By  

Oncology, Vol. 77, Iss. 6, 2010-02 ,pp. : 395-399

Karger

Access to resources Recommend Favorite

Everolimus Plus Exemestane in Postmenopausal Patients with HR⁺ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

By Yardley Denise   Noguchi Shinzaburo   Pritchard Kathleen   Burris Howard   Baselga José   Gnant Michael   Hortobagyi Gabriel   Campone Mario   Pistilli Barbara   Piccart Martine   Melichar Bohuslav   Petrakova Katarina   Arena Francis   Erdkamp Frans   Harb Wael   Feng Wentao   Cahana Ayelet   Taran Tetiana   Lebwohl David   Rugo Hope  

Advances in Therapy, Vol. 30, Iss. 10, 2013-10 ,pp. : 870-884

Springer Publishing Company

Access to resources Recommend Favorite

Epigenetic markers in circulating cell‐free DNA as prognostic markers for survival of castration‐resistant prostate cancer patients

By  

THE PROSTATE, Vol. 78, Iss. 5, 2018-04 ,pp. : 336-342

John Wiley & Sons Inc

Access to resources Recommend Favorite